Consistent with a role for EphA2 in NAFLD/NASH, global EphA2 KO mice show significantly lower indices of NAFLD following high fat diet feeding, including reduced hepatic steatosis and inflammation
Interaction with medicine: anticancer medications (arsenic trioxide) antimetabolites (mercaptopurine)RE antibiotics (chloramphenicol) oral contraceptives Interaction with Disease: hypokalaemia optic nerve damage malabsorption renal impairment Precautions and Warnings 1
Some patients benefit from a single treatment, while others choose a series of infusions for ongoing wellness and support
Cordoba-Lanus, E
8 Other specified nutritional anemias Anemia associated with deficiency of copper Anemia associated with deficiency of molybdenum Anemia associated with deficiency of zinc Excludes1: nutritional deficiencies without anemia, such as: copper deficiency NOS (E61.0) molybdenum deficiency NOS (E61.5) zinc deficiency NOS (E60) D53.9 Nutritional anemia, unspecified Simple chronic anemia Excludes1: anemia NOS (D64.9) Hemolytic anemias (D55-D59) D55 Anemia due to enzyme disorders Excludes1: drug-induced enzyme deficiency anemia (D59.2) D55.0 Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency Favism G6PD deficiency anemia D55.1 Anemia due to other disorders of glutathione metabolism Anemia (due to) enzyme deficiencies, except G6PD, related to the hexose monophosphate [HMP] shunt pathway Anemia (due to) hemolytic nonspherocytic (hereditary), type I D55.2 Anemia due to disorders of glycolytic enzymes Hemolytic nonspherocytic (hereditary) anemia, type II Hexokinase deficiency anemia Pyruvate kinase [PK] deficiency anemia Triose-phosphate isomerase deficiency anemia Excludes1: disorders of glycolysis not associated with anemia (E74.8) D55.3 Anemia due to disorders of nucleotide metabolism D55.8 Other anemias due to enzyme disorders D55.9 Anemia due to enzyme disorder, unspecified D56 Thalassemia Excludes1: sickle-cell thalassemia (D57.4-) D56.0 Alpha thalassemia Alpha thalassemia major Hemoglobin H disease Severe alpha thalassemia Triple gene defect alpha thalassemia Excludes1: alpha thalassemia minor (D56.3) asymptomatic alpha thalassemia (D56.3) hydrops fetalis due to hemolytic disease (P56.-) D56.1 Beta thalassemia Beta thalassemia major Cooley'
According to their review, the clinical characteristics of other PAIS appear almost indistinguishable from long COVID as described above, including exertion intolerance, fatigue, neurocognitive and sensory impairment, sleep disturbances, joint and muscle pain, and non-specific symptoms that are often present but of variable severity
